API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The aim of the partnership is the contract development of a Single Pill, Biramlo, with a combination of two leading active ingredients,bisoprolol fumarate and amlodipine for the treatment of high blood pressure (hypertension).
Lead Product(s): Bisoprolol Fumarate,Amlodipine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Biramlo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Midas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 19, 2022
Details:
ANDA Approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets generic version of Ziac is a combination of a thiazide diuretic and a beta-blocker used to treat high blood pressure (hypertension).
Lead Product(s): Bisoprolol Fumarate,Hydrochlorothiazide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Combination-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
Details:
ATHENA Pharmaceutiques has acquire the Bisoprolol + Aspirin Capsules dossier as well as the patent for this product. It is a fixed dose combination of two reference agents improving compliance and adherence to treatment in the secondary prevention of cardiovascular disease.
Lead Product(s): Bisoprolol Fumarate,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Bisoprolol/Aspirin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Athena Pharmaceutiques
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 15, 2021